Table 2. Urinary AG31 test for the diagnosis of bladder cancers.

	Test							Validation
	AUC (95% CI)	Sensitivity	Specificity	PPV	NPV	Positive LR	Negative LR	AUC (95% CI)	Sensitivity	Specificity	PPV	NPV	Positive LR	Negative LR
BC vs HC+Cystitis+Nephritis+Prostatitis+RCC+PC
	0.9567 (0.9337-0.9797)	0.9076	0.9152	0.8978	0.9234	10.7002	0.1010	0.9760 (0.9694-0.9826)	0.9230	0.9292	0.9255	0.9269	13.0430	0.0829
BC vs HC
	0.9597 (0.9368-0.9826)	0.9076	0.9153	0.9435	0.8640	10.7098	0.1009	0.9801 (0.9741-0.9862)	0.9230	0.9442	0.9684	0.8686	16.5327	0.0815
BC vs Cystitis+Nephritis+Prostatitis
	0.9500 (0.9200-0.9801)	0.9076	0.9104	0.9653	0.7821	10.1350	0.1015	0.9714 (0.9636-0.9791)	0.9230	0.9108	0.9729	0.7728	10.3441	0.0845
BC vs RCC+PC
	0.9592 (0.9328-0.9856)	0.9076	0.9231	0.9824	0.6792	11.7989	0.1001	0.9720 (0.9644-0.9796)	0.9230	0.9170	0.9803	0.7273	11.1201	0.0840

HC, healthy control; BC, bladder cancer; RCC, renal cell carcinoma; PC, prostate cancer; AUC, area under curve; PPV, positive predictive value; NPV, negative predictive value; LR, likelihood ratio; CI, confidence interval.